January - March 2024
HTLV in Sweden
Abstract
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However, much of the epidemiological data on HTLV in Sweden stems from studies conducted primarily between the 1990s and 2007, and the impact of migration to Sweden during the past 15 years has not been evaluated. Despite Sweden’s status as a country with generally low prevalence of HTLV, it is prudent to anticipate and prepare for several potential challenges associated with HTLV infection in the future. Proactive measures to enhance awareness, alongside strategies to curtail transmission and mitigate complications, are crucial for addressing this relatively rare, but significant health issue. In this work, we review the current epidemiological knowledge about HTLV in Sweden and discuss future Swedish perspectives.
Keywords:
HTLV-1. HTLV-2. Adult T-cell leukemia/lymphoma. Tropical spastic paraparesis. Intravenous drug users. Sweden.
We respond to queries submitted by people who use our website contact forms. Your data is solely used for this purpose and will not be shared with third parties. You can find more information on the processing of your data by clicking on this link.
©2018 Permanyer Publications - Legal Notice - Data Protection Policy - Cookies Policy - ISSN 1139-6121- eISSN 1698-6997